Evidence map›Paper›PMID 38418611›Full record

ArticleLeukemia2024

Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Satu Mustjoki, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed and 10 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Hjalmar FlygtDepartment of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden. hjalmar.flygt@medsci.uu.se.ORCID http://orcid.org/0000-0002-8912-2324
Stina SöderlundDepartment of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.
Johan RichterDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.ORCID http://orcid.org/0000-0002-0374-6823
Susanne SausseleMedical Clinic, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0003-0357-5785
Perttu KoskenvesaDepartment of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Leif StenkeDepartment of Hematology, Karolinska University Hospital and Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Satu MustjokiDepartment of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.ORCID http://orcid.org/0000-0002-0816-8241
Andreja DimitrijevicDepartment of Hematology, Odense University Hospital, Odense, Denmark.ORCID http://orcid.org/0000-0002-0125-1886
Jesper StentoftDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Waleed MajeedDepartment of Hemato-Oncology, Stavanger University Hospital, Stavanger, Norway.
Lydia RoyFrench CML group Fi-LMC, Centre Léon Bérard, Lyon, Hôpital Universitaire Henri Mondor, AP-HP, Service d'hématologie Clinique & Faculté de Santé, Université Paris Est Créteil, Créteil, France.
Dominik WolfDepartment of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Tyrolean Cancer Research Institute (TKFI), Medical University Innsbruck, Innsbruck, Austria.
Arta DreimaneDepartment of Hematology, Linköping University Hospital, Linköping, Sweden.
Bjørn Tore GjertsenDepartment of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.
Tobias Gedde-DahlDepartment of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Erik AhlstrandDepartment of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Berit MarkevärnDepartment of Hematology, Umeå University Hospital, Umeå, Sweden.
Henrik Hjorth-HansenDepartment of Hematology, St. Olavs Hospital, Trondheim, Norway.
Jeroen Janssen *Department of Hematology, Radboud University medical center, Nijmegen, The Netherlands.
Ulla Olsson-Strömberg *Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38418611
PMCPMC10997495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.